Roche Holding AG Updates on Parkinson’s Disease Research
Roche Holding AG, a Swiss pharmaceutical company specializing in the development and manufacture of prescription drugs, has provided updates on its research for a Parkinson’s disease treatment.
The company has continued to progress in its research for Prasinezumab, a drug currently in Phase 3 trials. This development is part of Roche’s ongoing efforts to find a cure for Parkinson’s disease.
However, the company has faced setbacks in its research. A study for Venclexta, a different medication developed by Roche, was unsuccessful. Additionally, the company has halted development of Elevidys due to two patient fatalities.
As a result of the Elevidys setback, Roche’s stock has declined. Despite this, the company remains committed to its research for a Parkinson’s disease treatment.
Key Developments:
- Prasinezumab: Phase 3 trials ongoing
- Venclexta: Study failed
- Elevidys: Development halted due to patient fatalities
- Stock: Declined following Elevidys setback